{"groups":[{"description":"XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily","id":"FG000","title":"XL184 (Cabozantinib)"},{"description":"oral capsules once daily","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"9"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"5"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Did not receive drug"},{"reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"67"}],"type":"Disease progression per PI"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"data unavailable"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"comment":"Randomized","groupId":"FG000","numSubjects":"219"},{"comment":"Randomized","groupId":"FG001","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"comment":"Continuing treatment at data cutoff for primary analysis, but subsequently discontinued study","groupId":"FG000","numSubjects":"98"},{"comment":"Continuing study treatment at the time of data cut-off.","groupId":"FG001","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"96"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"First patient enrolled 10 September 2008, last patient enrolled 27 February 2011. Data cut off date 15 June 2011."}